1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

FDA partially grants petitions on bioequivalence guidance for generic Pentasa and Asacol

 
• By Nancy Faigen

The US FDA opposes the idea that applicants of generic or "follow-on" formulations of extended or delayed-release oral mesalamine drug products need to show bioequivalence to ulcerative colitis treatments Pentasa or Asacol through data from comparative clinical endpoint studies. This has dampened attempts by Shire and Warner Chilcott to use the citizen's petition process to put in place such criteria.

The US FDA opposes the idea that applicants of generic or "follow-on" formulations of extended or delayed-release oral mesalamine drug products need to show bioequivalence to ulcerative colitis treatments Pentasa or Asacol through data from comparative clinical endpoint studies. This has dampened attempts by Shire and Warner Chilcott to use the citizen's petition process to put in place such criteria.

But the agency, in its joint response issued 24 August, did agree to a request of both petitioners – that...

More from Alimentary/Metabolic

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.